title: Effects of diquafosol tetrasodium administration on visual function in short break-up time dry eye.
abstract: OBJECTIVE
  To investigate the effect of diquafosol tetrasodium on tear and visual function in short break-up time (sBUT) dry eye (DE).
  
  
  METHODS
  This interventional nonrandomized comparative study involved 11 eyes in 11 patients with sBUT DE (symptom-positive sBUT group) and 13 eyes in 13 volunteers with BUT values ≤5 s without DE symptoms (symptom-negative sBUT group). Tear function was assessed by measuring BUT and Schirmer values. Serial measurements were made of visual acuities (using a functional visual acuity measurement system) and higher-order aberrations (using a wavefront sensor). The parameters were compared before and 1 month after diquafosol tetrasodium instillation. Any changes in symptomatology after administration were also recorded.
  
  
  RESULTS
  After diquafosol tetrasodium administration, BUT values tended to increase in the symptom-positive sBUT group (P=0.07) and significantly increased in the symptom-negative sBUT group (P<0.05). LogMAR functional, minimal, and maximal visual acuities and higher-order aberrations significantly decreased after diquafosol tetrasodium administration in the symptom-positive sBUT group (P<0.05), while there were no significant changes in these values in the symptom-negative sBUT group (P>0.05). Diquafosol tetrasodium administration provided relief of DE symptoms in 75% of patients in the symptom-positive sBUT group.
  
  
  CONCLUSIONS
  Diquafosol tetrasodium appeared to improve tear film stability and visual function in sBUT DE.
authors.affiliation: Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan. fwiw1193@mb.infoweb.ne.jp
authors.forename: Minako
authors.initials: M
authors.lastname: Kaido
authors.forename: Miki
authors.initials: M
authors.lastname: Uchino
authors.forename: Takashi
authors.initials: T
authors.lastname: Kojima
authors.forename: Murat
authors.initials: M
authors.lastname: Dogru
authors.forename: Kazuo
authors.initials: K
authors.lastname: Tsubota
mesh_terms: D000328:Adult; D015352:Dry Eye Syndromes / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D009907:Optometry; D011122:Polyphosphates / Q000008:administration & dosage / Q000627:therapeutic use*; D058912:Purinergic P2Y Receptor Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D013666:Tears / Q000737:chemistry / Q000378:metabolism*; D013997:Time Factors; D016896:Treatment Outcome; D014500:Uracil Nucleotides / Q000008:administration & dosage / Q000627:therapeutic use*; D014792:Visual Acuity / Q000187:drug effects*
chemical_list: D009883:Ophthalmic Solutions; D011122:Polyphosphates; D058912:Purinergic P2Y Receptor Agonists; D014500:Uracil Nucleotides; C403315:diquafosol